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Abstract: Aflatoxin M1 (AFM1), a human carcinogen, is found in milk products and may have
potentially severe health impacts on milk consumers. We assessed the risk of cancer and stunting as a
result of AFM1 consumption in Nairobi, Kenya, using worst case assumptions of toxicity and data
from previous studies. Almost all (99.5%) milk was contaminated with AFM1. Cancer risk caused by
AFM1 was lower among consumers purchasing from formal markets (0.003 cases per 100,000) than for
low-income consumers (0.006 cases per 100,000) purchasing from informal markets. Overall cancer
risk (0.004 cases per 100,000) from AFM1 alone was low. Stunting is multifactorial, but assuming
only AFM1 consumption was the determinant, consumption of milk contaminated with AFM1 levels
found in this study could contribute to 2.1% of children below three years in middle-income families,
and 2.4% in low-income families, being stunted. Overall, 2.7% of children could hypothetically be
stunted due to AFM1 exposure from milk. Based on our results AFM1 levels found in milk could
contribute to an average of −0.340 height for age z-score reduction in growth. The exposure to AFM1
from milk is 46 ng/day on average, but children bear higher exposure of 3.5 ng/kg bodyweight
(bw)/day compared to adults, at 0.8 ng/kg bw/day. Our paper shows that concern over aflatoxins in
milk in Nairobi is disproportionate if only risk of cancer is considered, but that the effect on stunting
children might be much more significant from a public health perspective; however, there is still
insufficient data on the health effects of AFM1.
Keywords: urban consumers; cancer; stunting; milk; dairy products
Key Contribution: The contribution of AFM1 through dairy products to the incidence of
hepatocellular carcinoma is likely negligible. More evidence is needed to understand the contribution
of AFM1 on childhood stunting.
1. Introduction
Contaminants in foods causing health problems include pathogens and toxins, which are present
in raw materials or introduced during processing. Aflatoxins are mycotoxins produced by certain
fungi, ubiquitous in soils in tropical and sub-tropical areas. The maximum level for aflatoxins in
Toxins 2018, 10, 348; doi:10.3390/toxins10090348 www.mdpi.com/journal/toxins
Toxins 2018, 10, 348 2 of 15
foods are regulated in many countries due to their harmful effects on health, though the allowable
limits vary [1]. Aflatoxins, including aflatoxin B1 (AFB1) and aflatoxin M1 (AFM1), are the most potent
carcinogens among all mycotoxins and are classified as Group 1, meaning they have been proven to be
carcinogenic to humans [2].
The European Union (EU) regulation 1881/2006 [3] set the legal maximum limit for AFM1 in
raw milk at 0.05 ng/g, which is lower by one order of magnitude than the Codex Alimentarius
recommendation [4] of 0.5 ng/g. The Codex recommendation is assumed to be followed in the Kenyan
standards, although there is some confusion among stakeholders as to which aflatoxin standard applies
to milk [5].
In uncontrolled and unmonitored food production and distribution systems, aflatoxin levels in
foods can rise to alarming levels, resulting in acute and sometimes fatal illness. Aflatoxin B1 prevalence
is variable and affected by season, weather, geographic area, and storage conditions, among other
factors [6]. AFM1 is the 4-hydroxy derivative of AFB1, and the major toxin metabolite found in milk
and urine in animals and humans exposed to dietary AFB1 [7]. AFM1 is considered at least 10 times
less carcinogenic than AFB1, based on animal trials [8,9].
Severe aflatoxin poisoning, called acute aflatoxicosis, caused by consumption of large amounts of
aflatoxins, has occurred several times in Kenya resulting in hundreds of fatalities [6,10,11]. These cases
have increased awareness of the prevalence of aflatoxin in the feed and food chains leading to policy
change, public concern, research efforts, and mitigation interventions.
Carcinogenic effects have mainly been studied for AFB1, but all aflatoxins are believed to be
carcinogenic [2]. Aflatoxins are associated with liver cancer, which was estimated to have caused
745,000 deaths in 2012, mostly due to hepatocellular carcinoma (HCC) [12]. Similarly, Wong et al. [13]
estimated a global total of 782,451 new liver cancer cases and 745,533 related deaths per year based
on cancer reporting in 2012. Less developed regions bear 95% of the total liver cancer incidences and
96% of the mortality [13]. Risk factors for HCC include being male, lower socioeconomic status, and
poverty [13]. Infection with the hepatitis B virus (HBV) is one of most important risk factors. In hepatitis
B negative (HBsAg-negative) and hepatitis B positive (HBsAg-positive) populations, the burden of
HCC cases attributable to aflatoxins exposure worldwide, through maize and peanuts consumption,
was estimated to be 11–450 and 44–2270 annually, respectively [14]. Gibb et al. [15] estimated 22,000
(95% UI 9000–57,000) aflatoxin-related HCC cases globally in 2010 using the population attributable
fraction approach. Another approach found aflatoxin-attributable liver cancer burden globally to be
25,500–155,000 cases annually [16]. In the African region, it was estimated that aflatoxins cause 0.4
(0.1–1) deaths per 100,000 people annually [15].
Stunting, based on low height-for-age z-score (HAZ), is defined when height is more than two
standard deviations (SD) below the standard mean [17]. The HAZ score is a metric showing how
many standard deviations a child is from the mean height-for-age, and a HAZ of −2 means that a
child is stunted (more than two standard deviations below mean height); a HAZ of −3 is considered
severe stunting. Stunting is a well-established risk marker of poor child development and indicates
chronic malnutrition; it has been associated with chronic aflatoxin exposure [18,19]. Stunting and
growth impairment are major concerns [19,20] as stunting has serious impacts beyond childhood
resulting in lower school achievements, life-time earnings, increased health problems, and decreased
productivity [18,21]. Aflatoxin exposure, due to the suppression of the immune system causing
increased risk of infections or due to direct effects in the gut or liver, could potentially cause or
accelerate stunting risk and severity [18].
The AFB1 exposure association with stunting is considered likely to be causal, but the mechanisms
are yet to be proven and there are studies indicating a negative association between AFB1 exposure and
growth impairment or stunting [19,22–25] as well as studies where association between AFB1 exposure
and growth rate was not observed [26–28]. The variety in exposure levels and reduced growth levels
suggest a possible threshold of aflatoxins for observable growth impairment effect. However, it should
be noted that despite the association between aflatoxin exposure and growth impairment, many other
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factors have an influence on undernutrition, child development, and toxicity effects, including health
status, nutritional intake, food quality, poor sanitation, and general poverty [19,22,25,29,30].
In previous studies, AFM1 exposure in early life and childhood was associated with reduced HAZ
score in children [27], reduced birth weight [31], reduced height at birth [32], and stunted growth [33].
However, in the case of AFM1, there are fewer studies on the association with growth and no proven
causality or mechanism between stunting and exposure, which means that any risk assessment for
stunting is purely hypothetical.
World Health Organization (WHO) estimations of the global and regional disease burden of
foodborne chemical toxins [15] consider two approaches, top-down and bottom-up, for assessing
aflatoxin health burden and discuss why these differ. The top-down approach is based on estimations
of actual death and mortality cases, whereas the bottom-up approach uses exposure levels of diets
and contamination levels in foods to predict death and mortality [15]. Both approaches are prone to
biases: in particular, regional cancer registration data likely under-estimate cases due to limited health
care and failure of cancer diagnosis or under-reporting, especially in less-developed regions, whereas
predictive approaches may over-estimate cases [13].
Risk assessment of a chemical or compound through dietary exposure includes hazard
identification, hazard characterization, exposure assessment, and risk characterization [34]. In this
study, we conducted a predictive (bottom-up) risk assessment for AFM1 exposure, stunting, and cancer
risk among urban milk consumers in Nairobi, Kenya. Dietary exposure was derived from studies
conducted during 2013–2016 in Nairobi, Kenya, analyzing AFM1 levels in formal and informal dairy
products, milk consumption levels, and exposure of adults and children. Stunting risk was assessed
based on exposure and previous stunting prevalence [27]. To assess the risk of cancer caused by dietary
exposure to AFM1 through consumption of milk and milk products, exposure levels were calculated,
and data on estimated cancer cases were used.
2. Results
2.1. Milk Consumption of Adults
The analysis of milk consumption shows differences between consumer groups based on their
income status varying from 148 L annually in mid-income areas up to 240 L annually in low-income
areas. Table 1 shows the average consumption of milk by adults in low- and mid-income areas
based on self-assessments, portion estimations, and 24-h dietary recalls. From mid-income adult
respondents, 44% reported no milk consumption compared to 18% in low-income respondents.
Similarly, respondents in mid-income areas reported lower daily milk intake than in low-income
areas, 229 mL/day and 539 mL/day on average among all respondents, respectively.
Table 1. Reported milk consumption for adults in low-income (LI) and mid-income (MI) areas. Average
consumption is calculated both for all the respondents and among those respondents who reported
consuming milk.





All respondents 837 (100%) 437 (534) 160
Milk consumers 612 (73%) 589 (544) 214
LI respondents 543 (65%) 539 (599) 197
LI milk consumers 446 (82%) 657 (600) 240
MI respondents 294 (35%) 229 (294) 84
MI milk consumers 166 (56%) 406 (285) 148
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2.2. Milk Consumption of Children
Milk consumption for children below 3 years in low- and mid-income areas was calculated
combining several surveys using 24-h recall and self-reporting. The milk type was not specified
in the studies focusing on milk consumption of children. Table 2 shows the average reported
milk consumption among children in low- and mid-income households. The average values show
differences in consumption between areas.
Table 2. Milk consumption for children below three years old in low-income (LI) and mid-income (MI)
areas. No children were reported to not consume milk at all.





All children 473 (100%) 438 (437) 160
LI children 391 (83%) 398 (451) 145
MI children 82 (17%) 626 (299) 229
2.3. AFM1 Levels in Raw and Processed Milk Samples
Table 3 summarizes the combined data of all AFM1 analyses (N = 619) from the studies and
mean levels of AFM1 levels for different product groups collected from different income areas. Only
19 samples had levels above 0.5 ng/g of AFM1. Only three samples (3/619) were not contaminated
with detectable AFM1, and 99.5% were positive for aflatoxins, with the contamination level ranging
from 0 to 2.55 ng/g. The median for the AFM1 levels was lower than the mean, reflecting the large
standard deviation (SD), so the few samples with very high concentration raised the mean.
Table 3. Aflatoxin M1 (AFM1) levels for milk samples from informal and formal dairy chains in
low-income (LI) and mid-income (MI) areas, and samples exceeding the two most common limits of
0.5 ng/g and 0.05 ng/g.
Samples N (%)
AFM1 (ng/g) Samples above a Limit of
Mean SD Median 0.5 ng/g (%) 0.05 ng/g (%)
All 619 (100%) 0.105 0.195 0.059 19 (3%) 349 (56%)
Raw milk 1 368 (59%) 0.123 0.233 0.064 16 (4%) 225 (61%)
Processed milk 2 251 (41%) 0.079 0.116 0.049 3 (1%) 124 (49%)
UHT and pasteurized milk 178 (29%) 0.074 0.105 0.048 2 (12%) 86 (48%)
Fermented milk 3 73 (12%) 0.091 0.139 0.051 1 (1%) 38 (52%)
LI milk
All LI milk 463 (70%) 0.119 0.215 0.064 18 (4%) 287 (62%)
LI processed milk 95 (15%) 0.102 0.127 0.064 2 (2%) 62 (65%)
LI raw milk 1 368 (59%) 0.123 0.233 0.064 16 (4%) 225 (61%)
MI milk 4
Processed milk 156 (30%) 0.065 0.107 0.040 1 (1%) 62 (40%)
1 Raw milk samples were all from LI areas. 2 Processed milk includes samples from UHT (ultra-high temperature
processed) milk, pasteurized and fermented milk products available in LI and MI areas. 3 Fermented milk includes
samples from yoghurt and lala products. 4 Only processed milk samples were collected from MI area.
2.4. Exposure Assessment of Adults
Exposure to AFM1 from milk consumption was assessed based on milk consumption averages
in different income groups and average of AFM1 levels in milk and milk products. In Table 4,
the exposure levels of adults are summarized, using the mean contamination levels (Table 3) and the
mean consumption levels (Table 1).
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All consumers All milk 46 0.8
LI milk consumers All milk 69 1.2
Raw milk 81 1.4
Processed milk 1 52 0.9
Pasteurized and UHT milk 49 0.8
Fermented milk 2 60 1.0
LI milk 78 1.3
LI processed milk 67 1.1
MI milk consumers All milk 43 0.7
Processed milk 1 35 0.6
Pasteurized and UHT milk 32 0.5
Fermented milk 2 37 0.6
MI milk 27 0.4
1 Processed milk includes samples from UHT, pasteurized and fermented milk products. 2 Fermented milk includes
samples from yoghurt and lala products.
2.5. Exposure Assessment of Children
Exposure assessment for AFM1 from milk products was calculated for children below three years
old (Table 5) using the mean contamination levels (Table 3) and the mean consumption levels (Table 2).
The exposure was calculated based on milk consumption in different income areas and in AFM1 levels
found in milk and milk products.
Table 5. Exposure to AFM1 through different milk products among children below three years old
in low-income (LI) and mid-income (MI) areas. The exposure was calculated deterministically by




All children All milk 46 3.5
LI children All milk 42 3.2
Raw milk 49 3.8
Processed milk 1 31 2.4
Pasteurized and UHT milk 30 2.3
Fermented milk 2 36 2.8
LI milk 47 3.6
LI processed milk 40 3.1
MI children All milk 66 5.1
Processed milk 1 50 3.8
Pasteurized and UHT milk 47 3.6
Fermented milk 2 57 4.4
MI milk 41 3.2
1 Processed milk includes samples from UHT, pasteurized and fermented milk products. 2 Fermented milk includes
samples from yoghurt and lala products.
2.6. Assessment of Cancer Risk
For cancer risk assessment, estimations are summarized in Table 6 of AFM1-induced cancer risk
in different socioeconomic consumer groups exposed to AFM1 in milk. The Kenyan population is
estimated to be 46 million [35].
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Table 6. Annual risk for hepatocellular carcinoma (HCC) in per 100,000 people overall and then
Kenyan population, assuming AFM1 carcinogenicity of 10 times less than AFB1, categorized between
low-income (LI) and mid-income (MI) area consumers and milk category.
Cancer Risk Per 100,000 (95% CI) Kenya 1 (95% CI)
All 0.004 (0.000013–0.01) 1.7 (0.006–6.0)
LI consumers
All milk categories 0.005 (0.000016–0.02) 2.0 (0.008–7.5)
LI milk 0.006 (0.000019–0.018) 2.7 (0.009–8.7)
MI consumers
All milk categories 0.002 (0.000007–0.007) 0.9 (0.003–3.2)
MI milk 0.001 (0.000005–0.005) 0.6 (0.003–2.3)
Processed milk 0.003 (0.000012–0.011) 1.4 (0.005–5.3)
Raw milk 0.004 (0.000014–0.015) 2.0 (0.006–7.1)
1 Kenyan population is estimated 46,000,000 [35].
2.7. Risk Assessment of Stunting
The growth reduction estimation for children below three years exposed to AFM1 from milk,
based on different consumption levels of milk in different income areas and AFM1 levels in milk is
summarized in Table 7. In average, AFM1 can have an effect of −0.340 on height-for-age z-score,
contributing to 2.7% of childhood stunting (−2 or more reduction in height-for-age z-score).
Table 7. Growth reduction as a reduction in mean height-for-age z-score (HAZ) in children related to
AFM1 exposure from milk consumption categorized by low-income (LI) and mid-income (MI) areas.
Growth Reduction HAZ (95% CI) % Children −2 HAZ
All children −0.340 (−1.254, −0.003) 2.7%
LI children
All milk −0.314 (−1.170, −0.003) 2.4%
LI milk −0.358 (−1.297, −0.003) 2.8%
MI children
All milk −0.503 (−1.741, −0.014) 4.1%
MI milk −0.337 (−1.136, −0.011) 2.1%
3. Discussion
This risk assessment used milk consumption and milk contamination data from several studies
conducted in Nairobi in order to understand the potential impact of aflatoxin contamination on the
health of the urban population. While this analysis included observations from several surveys,
the assessment is not as strong as it could have been if it were possible to include the same number of
participants and directly measure milk consumption and test the different products consumed directly.
This approach would have allowed confidence ranges using deterministic exposure assessments.
Despite this, the levels used for the risk assessment reflect the distribution of samples in Nairobi,
and the reported consumption is from consumers purchasing milk in the same area.
3.1. Milk Consumption
Based on our results, daily average milk consumption was estimated to be approximately 440 mL
in adults, with low-income milk consumers consuming more (660 mL) than mid-income consumers
(400 mL). The estimate of milk consumption in low-income areas may have been biased because
some of the interviewed were milk traders, who have better access to milk. However, the significant
number of mid-income participants stating no milk consumption (44%) is in line with lower averages
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in consumption levels. The decreasing consumption of liquid milk and replacement of traditional
foods with high-value (processed) products along with increasing income is a global phenomenon.
Contradicting the milk consumption of adults, mid-income children below three years old
consumed more milk daily (630 mL) than low-income children (400 mL). The observed variance
among low-income children is higher than the average indicating wide disparity among milk intake in
low-income areas. This is consistent with a common belief that milk is especially suited to children.
However, this study was not concerned with the origin of the milk, but merely draws attention
to the potential risk effects of aflatoxins associated with milk consumption on urban consumers.
The confidence intervals of the estimates overlap, so a difference cannot be definitively claimed.
The different methods used to obtain the consumption data (24 h recall and self-reporting) produced
different estimates, with the studies using self-reporting estimating the consumption higher than
studies using 24 h recall (complementary data). These differences were also to be expected.
3.2. AFM1 Levels
The prevalence and levels of AFM1 in milk and milk products in urban Nairobi are concerning.
Aflatoxin levels in different product groups available in different income areas showed a trend of
lower aflatoxin levels in products available in mid-income area and in all processed milk samples.
The lower aflatoxin levels in processed milk samples could be the result of formal monitoring and
control systems, although we do not have evidence of the extent to which these are practiced in Kenya.
Clearly, the lack of any monitoring systems in informal markets enables contaminated products to be
available in the markets.
Whether the lower aflatoxin levels in processed and mid-income area samples are due to stricter
control or different production systems, there are still challenges. Only 3% of the samples were
non-compliant with detected concentrations above the limit of 0.5 ng/g AFM1 in milk, but 56% of
the samples had AFM1 concentrations above 0.05 ng/g. All mean levels in all categories were above
0.05 ng/g. Although processed milk samples had with lower AFM1 levels, 49% were above 0.05 ng/g.
It is not clear which level Kenya officially follows, which is creating confusion among stakeholders in
the markets.
Exposure to AFM1 is likely a long-standing problem, and during past 10 years, no improvement
has been observed in the contamination prevalence, with almost all milk being contaminated with
AFM1 [10,36–40].
In the global context, AFM1 levels found in Kenyan milk are high. Milk in Europe is most often
analyzed for AFM1, but is also the safest. The least amount of data is available from African countries,
but the available data imply highest prevalence and frequent detection levels [41,42]. In Brazil, 83% of
the milk samples tested positive for AFM1, in a range of 0.008 to 0.760 ng/g [43] and in India, almost
half of the analyzed milk was contaminated, with 44% being above EU limit [44].
3.3. Exposure
Total estimation of AFM1 exposure was 46 ng/day on average (0.8 ng/kg bw/day). Low-income
consumers had higher estimated exposure levels, at 69 ng/day (1.2 ng/kg bw/day), than the
mid-income consumers at 43 ng/day (0.7 ng/kg bw/day). The difference in exposure levels can
be explained by lower milk intake levels among mid-income consumers, and lower levels of AFM1
analyzed in samples acquired from middle income areas. Sources of potential inaccuracy in these
estimates include: milk consumption reported by respondents could be inaccurate, consumption
data focused only on liquid milk, consumers of one income bracket may purchase milk in areas of
another income bracket, AFM1 content most likely varies between batches, and there may be seasonal
differences [45]. However, overall exposure to AFM1 from milk seems to be high and chronic.
Calculated exposure levels of children below three years to AFM1 were significantly higher than
in adults, with the same total intake (46 g/day) but higher intake per bodyweight (3.5 ng/kg bw/day),
due to relatively high average milk consumption and low body weight. Adults and children in
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low-income areas were more exposed to AFM1, especially when consuming milk sourced from
low-income areas. Mid-income children were estimated to consume 41 ng/day (3.2 ng/kg bw/day)
of AFM1 through milk sourced from mid-income areas compared to the exposure of 47 ng/day
(3.6 ng/kg bw/day) in low-income children consuming milk sourced from low-income areas.
Another study of milk consumption and AFM1 concentration in the milk samples [36] estimated
the daily exposure to AFM1 from milk at 94 ng/per day for children and 120 ng/day for adults, which
is even higher than our estimations, but the study focused on milk retailers’ households where the
milk consumption was reported to be significantly higher (900 mL/day for adults and 730 mL/day
for children).
The Codex Alimentarius committee compared the consequences of setting the maximum
allowable limit to 0.05 ng/g versus 0.5 ng/g for AFM1 in milk. The recommended standard 0.5 ng/g
was based on the data available summarizing the estimated exposure levels; intakes of AFM1 from
milk was estimated 0.030 ng/kg bw/day and based on milk consumption levels exposure was
estimated to be 0.023 ng/kg ng/kg bw/day when a maximum level of 0.5 ng/g was used, and
0.0035 ng/kg bw/day for a maximum level of 0.05 ng/g [46]. Clearly, the exposure levels in urban
Nairobi are significantly higher.
3.4. Cancer Risk
The results show a low risk for cancer due to AFM1 exposure from milk consumption for
adults. Assuming levels and consumption were similar throughout Nairobi (a reasonable assumption),
there would be 0.04 cases per year for an urban population of 1,000,000 (26% of total population [35]),
which would translate to less than two cases per year for the whole of Kenya, assuming the exposure
was similar throughout the population, which is unlikely. The estimates are, however, more uncertain
than those for AFB1, since there is more uncertainty about the carcinogenicity of AFM1. In this study,
we assumed that the potency was 10 times lower, which is based on data from rodent trials [8].
Even though the cancer risk from AFM1 was low in this study, the effects of AFM1 on health,
and especially the combined effects of mixtures of mycotoxins, aflatoxins, other dietary contaminants,
alcohol consumption, and poor diet on cancer risk still remains largely unknown. The combined
exposure to different aflatoxins, mycotoxins, and other contaminants in foods might cause more
significant or unknown risks [15]. There is a possibility of a cumulative effect. Still, there does seem to
be a disconnection between the levels of expressed concern of consumers over aflatoxin in milk [47]
and the relatively low estimated mortality. Consumers often appear to have higher concern over
chemicals in food, although experts generally agree that biological hazards present greater risk [48].
3.5. Growth Reduction
Based on our findings, levels of AFM1 exposure from milk could contribute to HAZ reduction
of −2 or more in 2.7% of children. The mean average growth reduction in HAZ score from AFM1
exposure from milk would be −0.340. Mahdavi et al. [33] reported a −0.31 HAZ z-score reduction in
infants below three months consuming breastmilk with an AFM1 mean concentration of 9.69 pg/mL,
which is in line with our findings. Aflatoxin M1 exposure was reported to be inversely related to growth
in infants below six months, with a −0.013 z-score reduction in HAZ with increasing exposure [49].
This study found a higher exposure (11.3 ng/kg bw/day) than we observed, but our observation
resulted in a more significant reduction in height-for-age z-score among older children (up to three
years). Abdulrazzaq et al. [50] found a strong negative correlation between AFM1 levels both in
umbilical cord blood and maternal serum and birth weight of the infants. Again, AFM1 was detected
in 98% of samples with a median concentration of 8.2 ng/kg in breastmilk (n = 160), and was associated
inversely with height of infants at birth [32].
All these studies focused on infants and breastmilk, whereas ours focused on children consuming
bovine milk. Moreover, although several studies showed associations between aflatoxin and stunting,
correlation does not imply causation, and it is still not definitively proven that aflatoxin contributes
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causally to stunting, or the magnitude, if any, on the effect on growth. In addition, estimates of
contribution to stunting or based only on the effects of AFM1, not considering that increased milk
consumption by itself promotes child growth [51], nor any other dietary, health, or sanitary factors. It is
suggested that a daily consumption of 245 mL milk most likely has an additional effect of increasing
height by 0.4 cm annually [52]. As observed in previous studies with AFB1 and stunting association,
varying results from different studies can be due to, among other reasons, the general initial health
status of the studied cohort [25,26].
3.6. Overall
Risk assessments inevitably simplify complex processes. A number of studies have examined
associations between AFB1 exposure and stunting, with variable results, but there has been less
research on AFM1 exposure from milk in young children. Although some studies have analyzed the
association between AFM1 in breast milk and maternal blood and stunting [32,33,49,50], only one
study provided an estimate based on consumption of cow milk. This estimate was used in our study,
but the limited number of studies makes the estimate more uncertain [27].
Assuming that the estimate would be correct, and without taking the growth promotion from milk
itself into account, our results indicate that aflatoxins could contribute to a non-negligible proportion
of stunting cases and severity. Our study did not take any other dietary exposure or health status
into consideration. Our results would imply that, when considering aflatoxins in milk, stunting and
exposure to AFM1 may be a more serious public health consequence than liver cancer, but there is too
little evidence to be certain of this. Whether the AFM1 can be linked to stunting or not, the exposure
levels are evidently high among urban Nairobi children and adults consuming milk, which can be
a cause of concern for consumers and policymakers, although not to an extent to deter people from
consuming milk.
It is also important to understand the results in the context of the increasing trend in global food
trade as no market remains in isolation. Food is traded more than ever [53] and as markets for higher
quality food emerge, there is an increasing possibility that poor quality food is channeled to consumers
with low purchasing power. Food safety should be a default to all consumers and not be based on
socioeconomic status.
However, food security is still an issue in Kenya, and there is a trade-off when applying strict
regulatory limits [5]. Optimally, when deciding on the limits to apply in a country, it is recommended
that a Margin of Exposure approach be used [54], but in many countries, particularly in low- and
middle-income countries, regulatory limits are often adopted from trade partners or driven by public
concerns, even when there are few means of implementation. Difficulties in obtaining the current valid
standards for food products, including milk, and confusion over the standards for aflatoxin in milk
in Kenya is not facilitating implementation. Available and official documentation refer to different
levels [5,55,56], which can create frustration, confusion, and ignorance among producers. The costs of
purchasing official standards may deter small-scale producers from acquiring them and hence impede
implementation. There is an urgent need to have a clear communication about the regulations for the
successful control and monitoring implementation among all stakeholders.
Overall, there seems to be no change in the AFM1 situation in Kenyan dairy markets since the
aflatoxin problem became evident to large community in 2004, directly reflecting the dysfunctional
control systems and failed interventions. To strengthen national, safe, and high-quality dairy
production now and in the future, drastic changes must happen in the dairy markets.
4. Conclusions
We conclude that evidence of the harmful effects of AFM1 is scarce, and that more information
should be collected in order to warrant the strict standards imposed in many parts of the world.
This study also shows that consumers purchasing dairy products from informal markets are more
likely to be exposed to AFM1 than middle-income consumers purchasing processed products. The focus
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of future studies should be on exposure from complete diets and a range of contaminants. Also, the
economic costs and benefits of standards, and the feasibility of implementation, should be taken into
consideration, especially for less developed countries where less strict limits might be in place. Overall,
in light of the present evidence on the negative health effects of AFM1, this study indicates that milk
may contribute to a non-negligible health burden, but that further research should focus on possible
impacts on stunting, as this is by far the greatest potential negative health impact.
We acknowledge the limitations and uncertainty within this study. Most important were the
limitation of available data and lack of known confounders and mechanisms of how AFM1 might
cause stunting, either directly or indirectly. Longitudinal, cross-sectional, or ideally a clinical trial and
multidisciplinary studies would be required to better understand the effects of AFM1 of milk on child
development. Even more importantly, measures to generally improve food safety and mitigate food
safety hazard prevalence in food and feed chains should be a high priority especially in countries
where the burden of foodborne disease is very high.
5. Materials and Methods
We conducted a risk assessment for AFM1 in milk by combining AFM1 exposure data from several
studies conducted in low- and mid-income areas in Nairobi County between 2013 and 2016 [27,36,45].
The low-income areas where data were collected were Korogocho and Dagoretti—two informal
settlements dominated by informal supply chains. The mid-high-income area of study, Westlands, is
characterized by supermarkets and shopping centers and considered an expensive area to live. Income
status of the study areas was determined by the reported income of the households: low-income
households were those earning less than 20,000 Kenyan Shillings (KES)/month [57] and mid-income
areas were identified based on local expert opinion and consensus.
In brief, the different data sets that were summarized included:
(1) Data from a survey among informal milk traders in the low-income area of Dagoretti, Nairobi,
which included consumption data of milk-trading families and AFM1 levels in raw milk [36].
In total, 200 samples of raw milk were analyzed for AFM1 and 250 traders provided data on
milk consumption in their families. The milk consumption estimations were self-reported by
the families. This study also concluded that most traders supplied milk directly from farms,
which means that the source of the milk is close to the trading point. Daily AFM1 exposures
were calculated.
(2) Data from a survey on milk consumption in children (below 3 years) from two low-income areas
in Nairobi (Korogocho and Dagoretti) and the levels of AFM1 in the milk they consumed [27,57].
This study contained data on milk consumption for 204 children, of which 41% were stunted, and
128 raw milk samples were analyzed for AFM1 with ELISA.
(3) Data on milk consumption in adults and children (below 2 years) in the low-income area of
Dagoretti and the mid-high-income area of Westlands [47,58]. In the two areas, 323 and 299 adults,
respectively, were interviewed for theirs and their family’s milk consumption habits; results were
reported self-estimations.
(4) Data on AFM1 levels from milk sampled from raw and processed milk sampled in the low-income
area of Dagoretti and the mid-high-income area of Westlands [45]. This study analyzed the levels
of AFM1 in 291 different milk products, including both raw and processed samples.
Milk consumption estimations were conducted from a 24-h dietary recall study, portion
estimations [27,57], and self-reported consumption by the respondents [36,47,58]. For exposure,
we used an overall daily milk consumption levels for adults of 437 mL/day, and 657 mL/day for
low-income milk consumers and 406 mL/day for mid-income milk consumers. Milk consumption
estimates of 438 mL/day for children overall, and 398 mL/day for low-income area children and
626 mL/day for mid-income area children were used.
Toxins 2018, 10, 348 11 of 15
Exposure was calculated for all the samples, product categories, both income area sources, and
respective income area for the consumer group to highlight the differences in exposure. Processed
products were all milk products, except raw milk samples, and were also sub-divided between the
heat-treated and fermented products. Milk samples from mid-income areas were only processed milk
samples, and samples collected from low-income areas included both raw and processed milk.
The exposure was calculated deterministically by multiplying mean contamination level with
mean consumption level and divided by body weight of estimated average 60 kg for adults based on
mycotoxin safety evaluation for intake [59] and 13 kg for children below 3 years old. The exposure
data were divided into different categories to show the exposure levels according to income areas and
the product categories. Exposure was calculated for all the samples, milk source area, and respective
income area for the consumer group to highlight the differences in exposure.
AFM1 levels in milk in the above studies were all analyzed with enzyme-linked immune-sorbent
assay, using a commercial competitive ELISA (Helica AFM1 high sensitivity ELISA, Cat. No.
961AFLM01M-96) [27,36,45]. A total of 619 milk samples were analyzed for AFM1 levels.
For the risk assessment of stunting and cancer, distributions were fitted using @Risk 7.5 Industrial
(Palisade Corporation, Ithaca, NY, USA) for the following categories: AFM1 levels in raw and
processed milk and in total, in low-income areas, and in high-mid-income (mid-income) area; and milk
consumption in total, in low-income areas, and in high-mid-income (mid-income) area, for adults and
children, respectively.
Stochastic calculations were conducted using Monte Carlo simulations with 100,000 iterations
in @Risk and the distributions for AFM1 levels and milk consumption best fitting to the reported
consumption. When exponential distribution of milk consumption was used, the distributions were
truncated to not exceed 3000 g for children and 4000 g for adults (Table S1 in supplementary materials
lists all parameters). The body weight for adults was assumed to be 60 kg [59], and normally distributed
with a 5 kg standard deviation, assuming a slight increase in average body weight [60]. Since milk
consumption for children was collected for either below 2 or below 3 years of age, body weight was
assumed to be 5–15 kg, and uniformly distributed. For the purpose of this study, we assumed that
milk consumption and body weight were uncorrelated within age groups.
The cancer potency for aflatoxins has been assumed to be 0.01 cases per 100,000 people annually
for each ng/kg bodyweight (bw) consumed per day, among people not infected with hepatitis B virus,
and 30 times higher among those infected [14]. The prevalence of hepatitis-B-infected individuals used
was 13% in Kenya based on earlier studies [14]. The risk for liver cancer was calculated for adults by
multiplying the daily exposure with a worst-case and best-case potency and presented as the mean
risk per 100,000 urban inhabitants and the overall Kenyan population with a 95% confidence limit.
Compared to AFB1, AFM1 is believed to be less carcinogenic, with at least 10 times less
carcinogenicity [8], although both are classified as Group 1 carcinogens [2]. As the AFM1 data
are limited, the AFB1 potency provides information estimation about the AFM1 potency. For this risk
assessment, an estimate was done first using the estimate of potency suggested by the WHO, which is
also an estimate 10 times lower, which then provides scenarios for cancer risks.
There are not many published associations between AFM1 in milk and stunting, but the estimate
found by Kiarie et al. [27] in Kenya showed that the height-for-age adjusted z-score (HAZ score)
decreased by 0.09 (standard deviation 0.045) for every increase of 1 ng AFM1/kg bw/day. This estimate
is higher than found in other studies [49], but was used here for a worst-case scenario of the growth
impact. The impact of AFM1 on HAZ score was assumed to be normally distributed but truncated
at ±2 SD (thus only allowing the impact of AFM1 to vary between −0.18 and 0 for each increase in
exposure) in order not to have extreme values for the sake of the model. The impact on HAZ for a child
was calculated by multiplying the total exposure of AFM1 with this distribution, and then calculate
the percentage that had a resulting HAZ of 2 or more out of the 100,000 iterations.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/10/9/348/s1,
Table S1: The risk assessment parameters which were used in @Risk modeling.
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